Media ReleasesNext Science

View All Next Science News


Next Sciences XPERIENCETM cleared by TGA for sale in Australia


Next Science Limited (ASX:NXS) (Next Science) is delighted to announce that its proprietary XPERIENCETM Surgical Solution has been cleared by Australia’s Therapeutic Goods Administration (TGA).

The TGA clearance allows for the sale of XPERIENCETM in Australia.

XPerienceTM is designed for use in virtually every open surgical procedure as a single step (no wash out) application where the residual solution remains in the surgical site after closure. The continued presence of XPERIENCE will help to defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.